Tolvaptan
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Tolvaptan
- Tolvaptan: From Hyponatremia (SIADH) to Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Tolvaptan: From Hyponatremia (SIADH) to Autosomal Dominant Polycystic Kidney Disease (ADPKD)
One-Sentence Summary
Tolvaptan is a vasopressin V2-receptor antagonist historically used to treat hyponatremia related to SIADH, heart failure, and cirrhosis. The TxGNN model's top prediction points to Polycystic Kidney Disease 3, with or without Polycystic Liver Disease — a rare monogenic variant within the broader Autosomal Dominant Polycystic Kidney Disease (ADPKD) spectrum — and this direction is backed by two landmark completed Phase 3 RCTs (TEMPO 3:4, REPRISE) plus 20 supporting publications, including consensus guidelines and a Cochrane systematic review. Notably, tolvaptan already holds approved ADPKD indications abroad (e.g., Jinarc/Jynarque in the EU/US/Japan), so this is best understood as the model correctly re-identifying an established, high-confidence indication rather than a purely novel signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hyponatremia due to SIADH (Samsca) — established global label; not confirmed in the Norway regulatory data pack, which currently lists 0 authorizations |
| Predicted New Indication | Polycystic Kidney Disease 3, with/without Polycystic Liver Disease (ADPKD/PLD spectrum) |
| TxGNN Prediction Score | 99.99% (rank 319 overall) |
| Evidence Level | L1 (≥2 completed Phase 3 RCTs: TEMPO 3:4, REPRISE) |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
DrugBank-sourced mechanism-of-action data is currently unavailable (data gap DG002). However, the literature evidence collected in this pack consistently and independently identifies tolvaptan as a selective vasopressin V2-receptor antagonist. By blocking V2 receptor signaling in renal collecting duct cells, tolvaptan reduces intracellular cAMP, which is the principal driver of cyst-lining epithelial proliferation and fluid secretion in polycystic kidney disease. This mechanistic link — cAMP suppression halting cystogenesis — is the pharmacological basis repeatedly cited across the ADPKD literature in this pack (e.g., PMID 35328738, 40126492).
The relationship between tolvaptan's original use (aquaresis in hyponatremia/fluid-overload states) and the predicted indication is mechanistically coherent: both applications exploit V2-receptor blockade, just in different target tissues (systemic water handling vs. renal cyst epithelium). Critically, this is not a speculative extrapolation — tolvaptan already carries approved ADPKD indications in the US, EU, and Japan (branded Jynarque/Jinarc), built on the same TEMPO 3:4 and REPRISE trials surfaced by this evidence pack. The TxGNN model is therefore reproducing a well-validated, real-world indication rather than proposing something untested.
One caveat: the specific predicted disease term is "Polycystic Kidney Disease 3" (a rarer PKD3 monogenic subtype, distinct from the far more common PKD1/PKD2-driven ADPKD). All clinical evidence in this pack (TEMPO 3:4, REPRISE, pediatric trials) was conducted in the broader ADPKD population, not PKD3 specifically. The ontology mapping likely captures the general ADPKD/PLD disease family, but this distinction should be verified before any indication-specific regulatory claim is made.
Clinical Trial Evidence
Currently no related clinical trials registered in the structured clinical_trials field for this indication. (Note: the pivotal trials establishing this indication — TEMPO 3:4 and REPRISE — are captured as published literature below rather than as registry entries in this data pull.)
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23121377 | 2012 | RCT (Phase 3, TEMPO 3:4) | NEJM | Tolvaptan slowed growth in total kidney volume and decline in eGFR in early-stage ADPKD |
| 29105594 | 2017 | RCT (Phase 3, REPRISE) | NEJM | Preserved kidney function in later-stage ADPKD; more frequent elevations in aminotransferase/bilirubin observed |
| 38091246 | 2024 | RCT (Pediatric, NCT02964273) | Pediatr Nephrol | Evaluated tolvaptan safety/pharmacodynamics in children (5–17y) with ADPKD |
| 37150675 | 2023 | Systematic Review/Meta-analysis | Nefrologia | Confirmed pooled efficacy and safety profile of tolvaptan in ADPKD |
| 39356039 | 2024 | Systematic Review (Cochrane) | Cochrane Database Syst Rev | Reviewed disease-modifying agents, including tolvaptan, for ADPKD progression prevention |
| 35134221 | 2022 | Consensus Statement | Nephrol Dial Transplant | ERA Working Group/PKD International consensus on evidence-based tolvaptan initiation in ADPKD |
| 40126492 | 2025 | Review | JAMA | Comprehensive ADPKD review covering pathophysiology and management, including tolvaptan |
| 35487607 | 2022 | Review | Clin Liver Dis | Confirms tolvaptan slows renal function decline and cyst growth in ADPKD/PCLD overlap |
| 35728731 | 2022 | Guideline (EASL) | J Hepatol | Clinical practice guideline for cystic liver disease, including the polycystic liver disease component |
| 35328738 | 2022 | Review | Int J Mol Sci | Reviews ADPKD cystogenesis pathophysiology and treatment advances |
Norway Market Information
Tolvaptan currently has no marketing authorizations on file in Norway (0 licenses; market status "Not Marketed"). No product/dosage-form data is available to summarize.
Safety Considerations
Please refer to the package insert for safety information — no structured warnings, contraindications, or DDI data are currently available in this evidence pack (flagged as Blocking data gap DG001).
That said, the pivotal REPRISE trial (PMID 29105594) explicitly reports more frequent elevations in liver aminotransferases and bilirubin with tolvaptan versus placebo — this hepatotoxicity signal is well documented in tolvaptan's approved labels elsewhere (boxed warning in the US) and should be treated as a known class-relevant risk pending confirmation of the local label.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Efficacy evidence for tolvaptan in ADPKD is exceptionally strong (L1 — two completed, published Phase 3 RCTs plus consensus guidelines), and the indication is already approved in major markets. However, Norway has zero existing authorizations and a Blocking data gap on local warnings/contraindications, so market entry cannot proceed without completing the safety dossier.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain the approved EU/Norway-equivalent SmPC (e.g., Jinarc) for TFDA-equivalent warnings and contraindications
- Resolve DG002 (High): confirm DrugBank MOA record to formally support the mechanistic rationale
- Verify whether the target ontology term (PKD3-specific) should be reconciled to the broader ADPKD (PKD1/PKD2) population studied in TEMPO 3:4/REPRISE
- Establish a hepatic monitoring protocol (LFTs) given the documented hepatotoxicity signal, before any Norway MAA submission
Note on lower-ranked predictions: Ranks 2–10 (renal-hepatic-pancreatic dysplasia, karyomegalic interstitial nephritis, thoracic malformation, Joubert syndrome, hypertrichosis, periodontal-component syndromes, Dandy-Walker malformation syndrome, etc.) carry L4–L5 evidence at best, with most literature hits assessed as irrelevant or off-target (e.g., the periodontitis literature retrieved for rank 9 has no mechanistic connection to tolvaptan). These are held (Hold) and not pursued further in this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.